NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / India News / Should I be worried if I have taken AstraZeneca's Covishield?
    Summarize
    Next Article
    Should I be worried if I have taken AstraZeneca's Covishield?
    Covishield's TTS risk sparks debate

    Should I be worried if I have taken AstraZeneca's Covishield?

    By Chanshimla Varah
    May 02, 2024
    03:44 pm

    What's the story

    AstraZeneca, the pharmaceutical company behind the Covishield COVID-19 vaccine, recently acknowledged the potential risk of Thrombosis with Thrombocytopenia Syndrome (TTS) as a side effect.

    This revelation has sparked a flurry of debates on social media concerning the safety of the vaccine.

    In India, AstraZeneca's COVID-19 vaccine, Covishield, is manufactured by Serum Institute of India (SII).

    Accusations have now been leveled against the Indian government for allegedly compromising public health by approving Covishield due to its supposed risk of TTS.

    Investigative findings

    TTS risk with Covishield: A closer look

    The debate has gained momentum after the parents of a woman who died after taking Covishield started legal proceedings against SII.

    Venugopalan Govindan, Karunya's father who died in July 2021, claimed AstraZeneca's acknowledgment came "too late."

    This begs the question of whether people should be concerned if they have had the Covishield vaccine.

    Yes, to a certain degree.

    Covishield is the most commonly used vaccine in India, but instances of TTS have been minimal.

    Vaccine impact

    Covishield in India

    An investigation by The Healthy Indian Project (THIP) has revealed that while TTS is indeed a potential risk associated with Covishield, it's extremely rare.

    TTS is a serious condition characterized by a low platelet count and blood clot formation, with symptoms such as shortness of breath, chest pain, headaches, and easy bruising.

    Claims suggesting that all Indians are at immediate risk from TTS due to government negligence are grossly exaggerated and misleading.

    Vaccine comparison

    Covishield and TTS: A global perspective

    In fact, TTS isn't exclusive to AstraZeneca's vaccine; Johnson & Johnson's Janssen vaccine also carries this risk.

    The World Health Organization (WHO) maintains that "like any medicine, vaccines can cause side effects. However, these are usually very minor...such as a sore arm or a mild fever. More serious side effects are possible but extremely rare."

    Expert opinion

    Medical advice on TTS symptoms post-vaccination

    Dr. Jayadevan, Co-Chairman of the National Indian Medical Association (IMA) Covid Task Force in Kerala, also echoed similar views, stating that TTS is "a rare occurrence following specific types of vaccines and other causes."

    He further recommended vigilance and seeking medical advice if TTS symptoms are experienced.

    Notably, amid the row Prime Minister Narendra Modi's photo was removed from COVID-19 vaccination certificates issued by the Ministry of Health and Family Welfare amid the COVID-19 vaccine scare.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    AstraZeneca
    COVID-19
    Covishield
    Johnson & Johnson

    Latest

    Why red cross symbols are appearing on Indian hospital rooftops  Hyderabad
    'Not one statement…against India': Pakistan MP slams 'coward' Shehbaz Sharif  Jammu And Kashmir
    Vijay Deverakonda is a magnificent saint in 'VD14' first look Rashmika Mandanna
    Trump hints at tariff relief for China—What's behind the shift?  China

    AstraZeneca

    After Pfizer, Oxford-AstraZeneca's COVID-19 vaccine approved in UK Oxford University
    UK's approval to Oxford-AstraZeneca vaccine paves way for India India
    COVAXIN is 200% safe: Bharat Biotech MD on efficacy concerns Ministry of Health and Family Welfare
    Vaccine transport from SII to start from January 11/12 Vaccine

    COVID-19

    WFH or WFO? Which is more preferable  Workplace
    Chinese province deletes COVID-19 mortality data: Report China
    Genetic quirk behind why some people don't get COVID-19 symptoms Research
    Assam: Engineer's COVID-19 lockdown love story ends in triple murder Assam

    Covishield

    COVAXIN, Covishield not linked to increased risk of blood clotting Coronavirus
    118-year-old woman possibly oldest in India to get COVID-19 vaccine Coronavirus Vaccine
    Covishield 90% effective if doses given 2-3 months apart: Poonawalla Vaccine
    SII fixes Covishield's price at Rs. 600 for private hospitals Coronavirus

    Johnson & Johnson

    J&J faulty hip-implants: SC closes case citing Center's compensation scheme Supreme Court Of India
    Indian-born billionaire bribed doctors with strippers, to prescribe addictive painkiller Microsoft
    Canadian firm announces coronavirus vaccine candidate; testing possible soon Canada
    Johnson & Johnson: COVID-19's vaccine will be ready by 2021 United States of America
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025